{"drugs":["Antihemophilic Factor VIII Fc Fusion Protein Recombinant","Eloctate"],"mono":{"0":{"id":"930978-s-0","title":"Generic Names","mono":"Antihemophilic Factor VIII Fc Fusion Protein Recombinant"},"1":{"id":"930978-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930978-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bleeding, Perioperative; Treatment and Prophylaxis - Hemophilia A:<\/b> minor surgery (50% to 80% of normal factor VIII level required) 25 to 40 international units\/kg IV every 24 hours for at least 1 day until healing achieved<\/li><li><b>Bleeding, Perioperative; Treatment and Prophylaxis - Hemophilia A:<\/b> major surgery (80% to 120% of normal factor VIII level required preoperatively and postoperatively) 40 to 60 international units\/kg IV preoperatively, followed by 40 to 50 international units\/kg IV after 8 to 24 hours and then every 24 hours to maintain factor VIII levels; continue for at least 7 days after adequate wound healing<\/li><li><b>Bleeding, To prevent or reduce frequency of bleeding episodes; Prophylaxis - Hemophilia A:<\/b> initial, 50 international units\/kg IV every 4 days; adjust dose based on patient response<\/li><li><b>Bleeding, To prevent or reduce frequency of bleeding episodes; Prophylaxis - Hemophilia A:<\/b> maintenance, 25 to 65 international units\/kg IV every 3 to 5 days<\/li><li><b>Bleeding; Treatment and Prophylaxis - Hemophilia A:<\/b> minor and moderate bleeding (40% to 60% of normal factor VIII level required) 20 to 30 international units\/kg IV every 24 to 48 hours until bleeding resolved<\/li><li><b>Bleeding; Treatment and Prophylaxis - Hemophilia A:<\/b> major bleeding (80% to 100% of normal factor VIII level required) 40 to 50 international units\/kg IV every 12 to 24 hours for 7 to 10 days or until bleeding resolved<\/li><\/ul>"},"1":{"id":"930978-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Bleeding, Perioperative; Treatment and Prophylaxis - Hemophilia A:<\/b> (6 years or older) minor surgery (50% to 80% of normal factor VIII level required) 25 to 40 international units\/kg IV for at least 1 day until healing achieved; repeat every 24 hours if needed<\/li><li><b>Bleeding, Perioperative; Treatment and Prophylaxis - Hemophilia A:<\/b> (6 years or older) major surgery (80% to 120% of normal factor VIII level required preoperatively and postoperatively) 40 to 60 international units \/kg IV preoperatively, followed by 40 to 50 international units\/kg IV after 8 to 24 hours and then every 24 hours to maintain factor VIII levels; continue for at least 7 days after adequate wound healing<\/li><li><b>Bleeding, Perioperative; Treatment and Prophylaxis - Hemophilia A:<\/b> (younger than 6 years) minor surgery (50% to 80% of normal factor VIII level required) 25 to 40 international units\/kg IV every 12 to 24 hours for at least 1 day until healing achieved<\/li><li><b>Bleeding, Perioperative; Treatment and Prophylaxis - Hemophilia A:<\/b> (younger than 6 years) major surgery (80% to 120% of normal factor VIII level required preoperatively and postoperatively) 40 to 60 international units\/kg IV preoperatively, followed by 40 to 50 international units\/kg IV after 6 to 24 hours and then every 24 hours to maintain target factor VIII levels; continue for at least 7 days after adequate wound healing<\/li><li><b>Bleeding, To prevent or reduce frequency of bleeding episodes; Prophylaxis - Hemophilia A:<\/b> (6 years or older) initial, 50 international units\/kg IV every 4 days; adjust dose based on patient response<\/li><li><b>Bleeding, To prevent or reduce frequency of bleeding episodes; Prophylaxis - Hemophilia A:<\/b> (6 years or older) maintenance, 25 to 65 international units\/kg IV every 3 to 5 days<\/li><li><b>Bleeding, To prevent or reduce frequency of bleeding episodes; Prophylaxis - Hemophilia A:<\/b> (younger than 6 years) initial, 50 international units\/kg IV every 4 days; adjust dose based on patient response<\/li><li><b>Bleeding, To prevent or reduce frequency of bleeding episodes; Prophylaxis - Hemophilia A:<\/b> (younger than 6 years) maintenance, 25 to 80 international units\/kg IV every 3 to 5 days<\/li><li><b>Bleeding; Treatment and Prophylaxis - Hemophilia A:<\/b> (6 years or older) minor and moderate bleeding (40% to 60% of normal factor VIII level required) 20 to 30 international units\/kg IV every 24 to 48 hours until bleeding resolved<\/li><li><b>Bleeding; Treatment and Prophylaxis - Hemophilia A:<\/b> (6 years or older) major bleeding (80% to 100% of normal factor VIII level required) 40 to 50 international units\/kg IV every 12 to 24 hours for 7 to 10 days or until bleeding resolved<\/li><li><b>Bleeding; Treatment and Prophylaxis - Hemophilia A:<\/b> (younger than 6 years) minor and moderate bleeding (40% to 60% of normal factor VIII level required) 20 to 30 international units\/kg IV every 12 to 24 hours until bleeding resolved<\/li><li><b>Bleeding; Treatment and Prophylaxis - Hemophilia A:<\/b> (younger than 6 years) major bleeding (80% to 100% of normal factor VIII level required) 40 to 50 international units\/kg IV every 8 to 24 hours for 7 to 10 days or until bleeding resolved<\/li><\/ul>"},"3":{"id":"930978-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bleeding, Perioperative; Treatment and Prophylaxis - Hemophilia A<\/li><li>Bleeding, To prevent or reduce frequency of bleeding episodes; Prophylaxis - Hemophilia A<\/li><li>Bleeding; Treatment and Prophylaxis - Hemophilia A<\/li><\/ul>"}}},"3":{"id":"930978-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930978-s-3-9","title":"Contraindications","mono":"life-threatening hypersensitivity reactions, including anaphylaxis, to recombinant antihemophilic Fc fusion protein, past history <br\/>"},{"id":"930978-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- hypersensitivity reactions, including anaphylaxis, may occur and require immediate discontinuation and initiation of appropriate treatment<\/li><li>Other:<\/li><li>-- development of neutralizing antibodies may occur; monitoring recommended;<\/li><li>-- higher or more frequent doses may be required in pediatric patients<\/li><\/ul>"},{"id":"930978-s-3-11","title":"Pregnancy Category","mono":"Antihemophilic Factor: C (FDA)<br\/>"},{"id":"930978-s-3-12","title":"Breast Feeding","mono":"<ul><li>Antihemophilic Factor: WHO: Compatible with breastfeeding.<\/li><li>Antihemophilic Factor: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"5":{"id":"930978-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Musculoskeletal:<\/b>Arthralgia (1.2%)<\/li><li><b>Other:<\/b>Malaise (1.2%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (0.6%)<\/li><li><b>Dermatologic:<\/b>Rash (0.6%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Antibody development, Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"930978-s-6","title":"Drug Name Info","sub":{"0":{"id":"930978-s-6-17","title":"US Trade Names","mono":"Eloctate<br\/>"},"3":{"id":"930978-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930978-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930978-s-7","title":"Mechanism Of Action","mono":"Antihemophilic factor VIII Fc fusion protein recombinant transiently replaces the missing clotting factor VIII necessary for hemostasis in patients with hemophilia A. The Fc region of the drug binds to the neonatal Fc receptor (FcRn). FcRn aids in delay of lysosomal degradation of immunoglobulins by cycling them through the circulation.<br\/>"},"8":{"id":"930978-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930978-s-8-24","title":"Distribution","mono":"<ul><li>Vss: 49.5 mL\/kg <\/li><li>Vss, pediatrics: 58.7 mL\/kg (2 to 5 years); 49.9 mL\/kg (6 to 11 years); 60.3 mL\/kg (12 to 17 years)<\/li><\/ul>"},"3":{"id":"930978-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance: 2.06 mL\/kg\/hr<\/li><li>Total body clearance, pediatrics: 3.88 mL\/hr\/kg (2 to 5 years); 2.7 mL\/hr\/kg (6 to 11 years); 2.66 mL\/hr\/kg (12 to 17 years)<\/li><\/ul>"},"4":{"id":"930978-s-8-27","title":"Elimination Half Life","mono":"<ul><li>19.7 hours<\/li><li>Pediatrics: 12 hours (2 to 5 years); 14.6 hours (6 to 11 years); 16.4 hours (12 to 17 years) <\/li><\/ul>"}}},"9":{"id":"930978-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV use only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>drug vial and prefilled diluent syringe should be at room temperature before use<\/li><li>carefully remove the backing from the vial adaptor package without removing the adaptor or touching the inside of the packaging; place the vial adaptor over the vial with the spike centered over the rubber stopper and push straight down until fully inserted; remove vial adaptor package<\/li><li>push the tip of the plunger rod into the end of the syringe provided and turn clockwise until attached; bend the cap until it snaps off and attach the tip of the syringe into the adaptor opening; inject diluent into vial<\/li><li>swirl the contents; do not shake; reconstituted solution should be clear<\/li><li>turn vial upside down and draw the solution into the syringe; dispose of the vial with the adapter still attached; do not touch the glass tip of the syringe until ready for use<\/li><li>use within 3 hours of reconstitution, protect from sunlight, and do not refrigerate<\/li><li>for IV use only; administer as IV bolus no faster than 10 mL per minute<\/li><li>do not administer in same tubing or container with other drugs<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930978-s-10","title":"Monitoring","mono":"<ul><li>plasma factor VIII levels (serial), for adequate response<\/li><li>plasma factor VIII inhibitor (neutralizing antibodies) levels; if inadequate response to appropriate doses<\/li><li>bleeding prophylaxis or control is indicative of efficacy<\/li><li>administration, during major surgery or life-threatening bleeding episodes<\/li><li>clinical signs and symptoms of factor VIII inhibitor formation<\/li><\/ul>"},"11":{"id":"930978-s-11","title":"How Supplied","mono":"<b>Eloctate<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/>"},"13":{"id":"930978-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report loss of efficacy with usual dose, as this may indicate neutralizing antibodies.<\/li><li>Side effects may include malaise or arthralgia.<\/li><\/ul>"}}}